Sanofi is actively pursuing strategic deals to rejuvenate its medicine pipeline ahead of the looming patent expiration for its blockbuster product, Dupixent. The French pharmaceutical giant is focusing on acquisitions and partnerships to strengthen its portfolio and secure long-term growth. By bolstering its pipeline, Sanofi aims to mitigate the impact of losing exclusivity on Dupixent, a revenue driver that significantly contributes to its earnings.
The company’s leadership is prioritizing innovative therapies and expansion into key therapeutic areas to maintain competitive momentum. These efforts come amid broader industry challenges as patent cliffs threaten revenue stability for major drugmakers. Analysts view the strategy as critical to sustaining investor confidence and positioning Sanofi for future success in a crowded and evolving market landscape.
Source: Wall Street Journal US Business · Summarized by HeadlinesBriefing